Last reviewed · How we verify

DTaP vaccine and IPV vaccine

Boryung Pharmaceutical Co., Ltd · Phase 3 active Biologic

DTaP vaccine and IPV vaccine is a vaccine Biologic drug developed by Boryung Pharmaceutical Co., Ltd. It is currently in Phase 3 development for Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in infants and children. Also known as: Boryung DTaP Vaccine Inj. (Prefilled syringe), IPVAX INJ. PREFILLED SYRINGE INJ.

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus.

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus. Used for Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in infants and children.

At a glance

Generic nameDTaP vaccine and IPV vaccine
Also known asBoryung DTaP Vaccine Inj. (Prefilled syringe), IPVAX INJ. PREFILLED SYRINGE INJ
SponsorBoryung Pharmaceutical Co., Ltd
Drug classvaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

DTaP vaccine contains inactivated toxins from diphtheria and tetanus bacteria plus acellular pertussis antigens, while IPV contains inactivated poliovirus particles. Together, they prime both humoral and cell-mediated immune responses to prevent these four infectious diseases. The combination formulation simplifies immunization schedules by delivering multiple vaccines in a single injection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTaP vaccine and IPV vaccine

What is DTaP vaccine and IPV vaccine?

DTaP vaccine and IPV vaccine is a vaccine drug developed by Boryung Pharmaceutical Co., Ltd, indicated for Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in infants and children.

How does DTaP vaccine and IPV vaccine work?

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus.

What is DTaP vaccine and IPV vaccine used for?

DTaP vaccine and IPV vaccine is indicated for Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in infants and children.

Who makes DTaP vaccine and IPV vaccine?

DTaP vaccine and IPV vaccine is developed by Boryung Pharmaceutical Co., Ltd (see full Boryung Pharmaceutical Co., Ltd pipeline at /company/boryung-pharmaceutical-co-ltd).

Is DTaP vaccine and IPV vaccine also known as anything else?

DTaP vaccine and IPV vaccine is also known as Boryung DTaP Vaccine Inj. (Prefilled syringe), IPVAX INJ. PREFILLED SYRINGE INJ.

What drug class is DTaP vaccine and IPV vaccine in?

DTaP vaccine and IPV vaccine belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is DTaP vaccine and IPV vaccine in?

DTaP vaccine and IPV vaccine is in Phase 3.

What are the side effects of DTaP vaccine and IPV vaccine?

Common side effects of DTaP vaccine and IPV vaccine include Injection site pain, redness, or swelling, Fever, Fussiness or irritability, Drowsiness, Loss of appetite.

Related